Detection of circulating tumor DNA (ctDNA) after resection of stage II colon cancer may
identify patients at the highest risk of recurrence and help inform adjuvant treatment …

Studies in multiple solid tumor types have demonstrated the prognostic significance of
ctDNA analysis after curative intent surgery. A combined analysis of data across completed …

Background In non-metastatic colorectal cancer (CRC), we evaluated prospectively the
pertinence of longitudinal detection and quantification of circulating tumor DNA (ctDNA) as a …

Background For patients with metastatic colorectal cancer, stratification for treatment
(surgery or chemotherapy) is often based on crude clinicopathological characteristics like …

Introduction Circulating tumor DNA (ctDNA) has been increasingly recognized as a
promising minimally-invasive biomarker that could identify patients with minimal residual …

Purpose: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early
relapse detection may have a major impact on treatment decisions and patient management …

Importance Novel sensitive methods for detection and monitoring of residual disease can
improve postoperative risk stratification with implications for patient selection for adjuvant …

Importance Adjuvant chemotherapy in patients with stage III colon cancer prevents
recurrence by eradicating minimal residual disease. However, which patients remain at high …

Simple Summary Patients with colorectal cancer without distant metastases are often cured
by surgical tumor resection. Follow-up is needed because of the risk of disease recurrence …

Purpose: We investigated whether detection of ctDNA after resection of colorectal cancer
identifies the patients with the highest risk of relapse and, furthermore, whether longitudinal …